Michael Halpin

Operates as a biopharmaceutical company which manufactures and markets two advanced cell therapy products for sports medicine and severe burn care

Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology

Functions as a College/University

Part of Sanofi, Sanofi Corp. is a biopharmaceutical company dedicated to improving health outcomes through innovative medicines, vaccines, and patient-centered care. The company is based in Bridgewater, NJ. The company offers a broad portfolio including prescription medicines across therapeutic areas such as immunology, neurology, oncology, rare diseases, cardiovascular disease, diabetes, and transplant, alongside an extensive range of vaccines protecting against infectious diseases like influenza, respiratory syncytial virus (RSV), dengue, and COVID-19. Sanofi emphasizes scientific innovation with a robust R&D pipeline comprising clinical-stage projects, including advanced therapies like bispecific antibodies, gene therapies, and mRNA vaccines. The company addresses complex conditions such as chronic graft-versus-host disease in transplant patients and rare blood disorders like immune thrombocytopenia purpura, having launched therapies in these areas. Sanofi collaborates with healthcare professionals, patient communities, advocacy groups, and governments to expand access, promote holistic care, and advance science. Social impact initiatives focus on health equity, inclusion, environmental factors affecting respiratory health, and responsible business practices. Sanofi provides resources for healthcare providers and patients, including prescribing information, patient support, and educational materials, and maintains transparent communication through media channels and regular updates on financial performance, regulatory approvals, and clinical trial progress.